Reanalysis of the ESPS 2 trial – Efficacy among high-risk subgroups
Project Objective
- Analyse clinical trial data from ESPS 2 to assess effectiveness of ER-DP + ASA vs. ASA in various risk subgroups
- Evaluate baseline subgroups in ESPS 2
Use baseline risk criteria from ESPS 2 to categorise and evaluate drug effect in low and high risk subgroups based upon different models (Framingham, Stroke Prognostic Index).
Outcomes
- Recurrent Stroke
- Stroke or Vascular Events (MI and vascular death)
References
Sacco et al. Arch Neurol 2005; 62 (3): 403-408.
PubMed Abstract
